Last updated: July 18, 2026
Delatestryl’s US investability hinges on: (1) US exclusivity and patent coverage in the Orange Book for testosterone cypionate injectable, (2) the practical generic entry landscape and expected pricing pressure, and (3) whether any manufacturer has enforceable formulation or method-of-use barriers versus approved generics. Without verified Orange Book listings, US approval details, patent numbers, and current litigation/ANDA status specific to Delatestryl, a complete, decision-grade patent and exclusivity map cannot be produced from the provided input.
What is Delatestryl (testosterone cypionate) and what products compete with it in the US?
Delatestryl is testosterone cypionate, an androgen used for conditions requiring androgen replacement. The investment relevance is not the molecule but the US regulatory “wrapper”: injectable testosterone cypionate generally faces high generic substitution once exclusivity ends, with economics driven by supply chain execution, labeling breadth, contracting, and vial/strength-specific competition.
Which dosage forms and strengths matter for market access
Investment models for injectable testosterone cypionate should be built on:
- NDC-level availability (strength, vial size)
- Contracting and wholesaler buying patterns
- Use in testosterone replacement therapy pathways (where applicable) and any specific label indications
What is the competitive set
The competitive set typically includes multiple FDA-approved generics and authorized versions of testosterone cypionate across manufacturers, with market share shifting quickly after generic launches.
What is the Orange Book status of Delatestryl and which patents protect it?
Featured-snippet answer: A decision-grade Orange Book status and protected-patent list cannot be generated without the specific FDA Orange Book record for Delatestryl (drug product/active ingredient, dosage form, route, strength, and Orange Book patent identifiers).
What to extract from the Orange Book for an investment model
A complete patent-and-exclusivity dashboard should include:
- Drug product record identifiers (active ingredient, strength, dosage form)
- Listed patents by type (composition, formulation, method of use, method of manufacturing, packaging)
- Patent expiration dates (and any statutory extensions)
- Exclusivity periods (drug product exclusivity, NCE/505(b)(2) where relevant, and pediatric exclusivity where applicable)
How patent coverage changes generic-entry timing
Even for older androgen injectables, investors must separate:
- Patent expiration for formulation or method patents that can delay “non-infringing” ANDA designs
- Exclusivity that can delay initial approvals independent of patents
- 180-day exclusivity for first paragraph IV filers if triggered
When does Delatestryl lose exclusivity in the US?
Featured-snippet answer: US exclusivity and patent-expiration timing for Delatestryl cannot be stated accurately without verified Orange Book listings for the relevant drug product record.
How investors should structure a loss-of-exclusivity forecast
Build a timeline that layers:
- Primary regulatory exclusivity end (if any)
- Earliest listed patent expiry (composition/formulation)
- Method-of-use and manufacturing patent expiry (if any)
- Any pediatric exclusivity extensions
- Any PTA-related changes to listed patent expirations
Generic launch scenario modeling
For injectable testosterone cypionate, economics depend on:
- Whether generic entrants can “design around” listed patents
- Whether paragraph IV challenges lead to delayed settlements
- Whether 180-day exclusivity is captured and by which filer
Which companies are challenging Delatestryl with ANDAs and Paragraph IV certifications?
Featured-snippet answer: ANDA/Paragraph IV challengers for Delatestryl cannot be enumerated without the specific FDA ANDA litigation and Orange Book patent-certification record tied to Delatestryl.
What to measure for Paragraph IV cases
A litigation-ready dataset must capture:
- Applicant/generic sponsor names
- ANDA application numbers
- Certifications to each Orange Book patent (I, II, III, IV)
- Filing dates
- Trigger events for 30-month stays
- Any settlement terms affecting launch dates
What patent litigation affects Delatestryl and what settlement agreements matter?
Featured-snippet answer: Litigation and settlement outcomes for Delatestryl cannot be listed without specific case dockets, parties, and settlement documents tied to the Delatestryl Orange Book patents.
Why litigation posture drives investment timing
For injectables, the return profile depends on:
- Whether a settlement delays generic entry and for how long
- Whether a court ruling narrows enforceable claims
- Whether an injunction is granted or stays are lifted
What formulations are protected for Delatestryl (composition, method-of-use, and manufacturing)?
Featured-snippet answer: A complete list of Delatestryl-protected formulations and manufacturing methods cannot be produced without verified Orange Book patent identifiers for the specific Delatestryl drug product record.
Typical patent categories investors look for in injectables
Once Orange Book data is available, map each listed patent to:
- Excipients and concentration ranges (composition/formulation)
- Sterility assurance and manufacturing steps (process)
- Drug product quality attributes that are tied to patent claims
- Any method-of-use claims tied to clinical endpoints
How does Delatestryl compare with other testosterone cypionate brands and generics on patent and exclusivity?
Featured-snippet answer: A comparative patent-and-exclusivity analysis requires verified Orange Book data for Delatestryl and its nearest US competitors. Without those records, no defensible ranking can be provided.
What investors should compare
- Earliest expiry among each company’s listed patents
- Whether competing brands have unique formulation/process patents
- Whether any competitor has active paragraph IV litigation with enforceable delay
What is the biosimilar risk profile for Delatestryl?
Delatestryl is not a biologic and is not in the biosimilar pathway. The main competitive risk is generic substitution via ANDAs, not biosimilar entrants.
What is the investment thesis for a testosterone cypionate injectable like Delatestryl?
A credible thesis for Delatestryl must be anchored to four fundamentals that determine risk-adjusted returns:
1) Regulatory and IP runway
- Patent-expiry cadence and whether any patents remain enforceable at the intended entry horizon
- Whether exclusivity barriers exist beyond core patent expiry
2) Generic substitution risk
- Number of approved competitors and whether multiple NDCs are liquid and price-competitive
- Whether any patented barriers block “drop-in” generic launches
3) Supply chain and execution
For injectable products, loss of exclusivity can quickly translate into price compression. Advantage accrues to manufacturers with:
- Stable manufacturing yields and low defect rates
- Contracting leverage and consistent inventory availability
- Tight lot traceability and pharmacovigilance execution
4) Revenue durability vs. contract pricing
Model revenue under:
- Wholesale and covered entity contracting dynamics
- Expected price erosion curve post entry
- Mix shifts by strength and vial size
Revenue exposure and downside scenarios for Delatestryl
A decision-grade revenue model requires current:
- US sales by NDC strength and year
- Gross-to-net dynamics (rebates, chargebacks)
- Contract duration and shelf-life inventory accounting
Those inputs are not included in the prompt, so only structurally correct scenarios can be stated:
- Base case: continued market share supported by supply stability and contracting despite generic competition
- Bear case: accelerated share loss and pricing pressure immediately after any enforceable barriers clear
- Bull case: delayed generic entry due to enforceable patents or settlements on key Orange Book listings
Key Takeaways
- Delatestryl investment fundamentals are dominated by US Orange Book patent and exclusivity status for testosterone cypionate injectable, plus the real-world ANDA and litigation timeline.
- Biosimilar risk is not applicable; the principal threat is ANDA generic substitution and any delay created by patent-enforcement outcomes.
- A complete decision-grade patent estate, exclusivity loss date, and litigation landscape cannot be produced from the provided input without the Delatestryl-specific Orange Book and ANDA/litigation record.
FAQs
- Which patents are listed in the Orange Book for Delatestryl (testosterone cypionate) injectable and when do they expire?
- What paragraph IV ANDA challenges exist for Delatestryl, and what are the expected launch dates if courts do not delay entry?
- Are there any method-of-manufacturing or formulation patents for Delatestryl that generics must design around?
- How should investors model price erosion for testosterone cypionate injectables after exclusivity ends?
- What regulatory changes or labeling updates typically affect market access and reimbursement for testosterone injectable products like Delatestryl?
References (APA)
- FDA Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. (US FDA). https://www.accessdata.fda.gov/scripts/cder/daf/
- FDA Drug Approvals and Databases (ANDA, Orange Book links). (US FDA). https://www.fda.gov/drugs/
